Αναζήτηση Δραστικών

NATALIZUMAB

ATC

Εμπορικές Ονομασίες

  • DRUGBANK - Natalizumab
  • indication:

    For treatment of multiple sclerosis.

  • pharmacology:

  • mechanism:

    Binds to the α4-subunit of α4b 1 and α4b 7 integrins expressed on the surface of all leukocytes except neutrophils, and inhibits the α4-mediated adhesion of leukocytes to their counter-receptor(s).

  • toxicity:

  • absorprion:

  • halflife:

    11 ± 4 days

  • roouteelimination:

  • volumedistribution:

    * 5.7 ± 1.9 L [Multiple Sclerosis (MS) Patients] * 5.2 ± 2.8 L [Crohn's Disease (CD) Patients]

  • clearance:

    * 16 +/- 5 mL/hour [patients with MS who did not have PML receiving the repeat IV administration of a 300 mg dose] * 22 +/- 22 mL/hour [Patients with Crohn's Disease receiving the repeat IV administration of a 300 mg dose]